Veracyte, Inc. (NASDAQ:VCYT) ranks among the many finest modern shares to purchase based on Wall Road analysts. On January 12, UBS reaffirmed its Purchase score for Veracyte, Inc. (NASDAQ:VCYT) alongside a value goal of $48. Analyst Lu Li retained a positive outlook after Veracyte’s This fall testing income exceeded expectations, which the corporate attributed largely to greater common promoting costs and prior-period collections reasonably than quantity development in Decipher assessments.
Veracyte’s 2026 testing income projections exceeded avenue expectations, and the corporate saved its projected adjusted EBITDA margin of 25%, up from about 21% in 2024, which UBS deems favorable for the inventory’s outlook.
The agency additionally famous potential good points from new product contributions, suggesting that the corporate’s present income projection doesn’t totally account for all development prospects.
General, Veracyte, Inc. (NASDAQ:VCYT) reported preliminary fourth-quarter 2025 income of $138-140 million, representing a 16%-18% year-over-year enhance that exceeded the consensus forecast of $132 million.
Veracyte, Inc. (NASDAQ:VCYT) is a genomic diagnostics firm that develops assessments to enhance prognosis and therapy selections for thyroid, lung, and different cancers, in addition to autoimmune illnesses.
Whereas we acknowledge the potential of VCYT as an funding, we consider sure AI shares supply larger upside potential and carry much less draw back danger. Should you’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 10 Finest Magic Formulation Shares for 2025 and 10 Finest Retirement Shares to Purchase In keeping with Hedge Funds.
Disclosure: None. This text is initially revealed at Insider Monkey.
